Literature DB >> 2870802

Dynamics of lymphocytic subpopulations in Friend leukemia virus-induced leukemia.

M Kitagawa, O Matsubara, T Kasuga.   

Abstract

The in vivo roles of the immunosurveillance mechanism of the host against leukemia induced by Friend leukemia virus (FLV) were examined. The significance of T-cells in host defense against FLV-induced leukemia was indicated by the fact that thymus-deprived C57BL/6N-nu/nu mice were sensitive to FLV, although normal C57BL/6N mice were, as already reported by many authors, resistant to FLV. In relation to the role of T-cells on the onset of FLV-induced leukemia, the population dynamics of the lymphocytic subpopulations of the systemic lymphoid organs after FLV injection in FLV-resistant C57BL/6N mice were examined in comparison with the dynamics in FLV-sensitive strains, C57BL/6N-nu/nu mice and normal C3H/HeN mice. In this system, Lyt-1+2- helper T-cells in the spleen of FLV-resistant C57BL/6N mice increased in number after FLV injection. The number of immunoglobulin positive cells did not remarkably change in FLV-resistant C57BL/6N mice after FLV injection, whereas the number increased in the lymph node of FLV-sensitive C3H/HeN mice. The results indicated that a major contribution to the relative susceptibility and resistance of the host to FLV was controlled by the capacity to mobilize T-cells to the spleen in an early stage of disease, although the interaction of these T-cells with other immune cells may play an important role in mediating host resistance to FLV-induced disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870802

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Natural killer cell suppression of Friend virus-induced preleukemic hemopoietic stem cells.

Authors:  R J Eckner; M Bennett; K L Hettrick; C Seidler
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

2.  Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.

Authors:  U Dittmer; K E Peterson; R Messer; I M Stromnes; B Race; K J Hasenkrug
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Lymphocyte deficiencies increase susceptibility to friend virus-induced erythroleukemia in Fv-2 genetically resistant mice.

Authors:  K J Hasenkrug
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Effects of type I interferons on Friend retrovirus infection.

Authors:  Nicole Gerlach; Simone Schimmer; Siegfried Weiss; Ulrich Kalinke; Ulf Dittmer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

5.  Induction of B-cell lymphoma in BALB/c nude mice with an ecotropic, B-tropic helper virus present in the murine AIDS virus stock.

Authors:  L Tayar; K Higo; Y Kubo; Y Wang; L M Lu; F Zhang; Y Iwatani; L Wang; T Ono; M Maeda; H Sakai; A Ishimoto
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Friend leukemia virus infection enhances DNA damage-induced apoptosis of hematopoietic cells, causing lethal anemia in C3H hosts.

Authors:  Masanobu Kitagawa; Shuichi Yamaguchi; Maki Hasegawa; Kaoru Tanaka; Toshihiko Sado; Katsuiku Hirokawa; Shiro Aizawa
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Differential requirements of cellular and humoral immune responses for Fv2-associated resistance to erythroleukemia and for regulation of retrovirus-induced myeloid leukemia development.

Authors:  Sachiyo Tsuji-Kawahara; Hiroyuki Kawabata; Hideaki Matsukuma; Saori Kinoshita; Tomomi Chikaishi; Mayumi Sakamoto; Yuri Kawasaki; Masaaki Miyazawa
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

8.  Minichromosome maintenance 2 bound with retroviral Gp70 is localized to cytoplasm and enhances DNA-damage-induced apoptosis.

Authors:  Shinya Abe; Morito Kurata; Shiho Suzuki; Kouhei Yamamoto; Ken-ichi Aisaki; Jun Kanno; Masanobu Kitagawa
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.